Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 13NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Somatostatinoma 1Multiple Endocrine Neoplasia Type 1 1

Interventions

Cyclophosphamide 388Specimen Handling 377Magnetic Resonance Spectroscopy 328Radiotherapy 306Biopsy 273Cisplatin 258Carboplatin 255Paclitaxel 235Doxorubicin 226Fluorouracil 200Etoposide 197Vincristine 183Bevacizumab 181Filgrastim 170Gemcitabine 163Leucovorin 149Cytarabine 144aldesleukin 141Taxes 127Docetaxel 122Chemotherapy, Adjuvant 114Oxaliplatin 113fludarabine phosphate 111Methotrexate 108Rituximab 107Radiation 106Bortezomib 105Prednisone 102Irinotecan 100Dexamethasone 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Cytidine Triphosphate × Clear all
NCT02101918 2020-03-23

Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 10 charts
Endocrine

Somatostatinoma, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡